RxDoctor Payments Data

Gina Micchia, DO

Family Medicine · Wake Forest, NCNPI 1548234347

Payments from drug & device makers

$624in general payments, 2019–2025

Across 21 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$325
  • Amgen$150
  • Lilly USA, LLC$60
  • Novo Nordisk$35
  • Astellas Pharma US Inc$25
  • Genentech USA, Inc.$16
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$80,286
Medicare patients
186
Services billed
1,045

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$78,399
MounjaroTirzepatide46$53,063
RybelsusSemaglutide15$33,064
EliquisApixaban11$14,454
JardianceEmpagliflozin15$12,640
Breo ElliptaFluticasone/Vilanterol27$12,400
TradjentaLinagliptin11$5,800
DuleraMometasone/Formoterol12$4,011
SynthroidLevothyroxine Sodium39$2,428
Levothyroxine Sodium197$2,168
Atorvastatin Calcium208$1,804
Losartan Potassium124$1,425
Metformin Hcl ErMetformin Hcl166$1,390
Wixela InhubFluticasone Propion/Salmeterol13$1,380
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$111,46383 claims
Lilly USA, LLCMounjaro$60$53,06346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wake Forest

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →